

IMPORTANT REMINDER TO HOLDERS OF WARRANTS OF AGILE THERAPEUTICS

As described in the Company's proxy statement filed in connection with acquisition of Agile by Insud Pharma, S.L. and the Current Report on Form 8-K disclosing the completion of such acquisition, holders of certain warrants previously issued by Agile are entitled to seek payment equal to the Black-Scholes value of such warrants based on the offer price per common share paid to holders of Agile's common stock in the acquisition (the "Merger Consideration") during the 30 day period following the closing, which period will expire on September 25, 2024. Holders of warrants have previously received details on the means by which such payments will be made and the documentation required by Agile to make the payments to which such holders are entitled, which in the case of warrants held through the book-entry system administered by The Depository Trust Company (CUSIP 00847L118) issued in October 2021 involves electronic submission entitling the holder to receive a Black-Scholes value of \$1.24 per warrant share (\$.000509 on a pre-reverse split basis), whereas warrants originally issued in physical form are to comply with the letter of transmittal process as detailed in such communications, entitling the holder to receive a Black-Scholes value specified therein. Any questions in this regard should be directed to Geoff Gilmore of the Company at +1 609 356-1931 or Jason Fantry of Broadridge at +1 631 274-2625. **Following the thirtieth day after the closing date, all outstanding warrants will represent only the right to receive the difference between the Merger Consideration and the applicable exercise price of such warrant. As a result of all such exercise prices exceeding the Merger Consideration, Agile expects any remaining warrants to be cancelled on the books of the Company.**